Will support the development of smart drugs for cancer
Cellectis, a France headquartered gene-editing company, has established a subsidiary, Cellectis, Inc, in New York at the Alexandria Center for Life Science, located on Manhattan’s east side.
The 12,000ft2 (approximately 1,100m2) US headquarters includes research laboratories to support the development of the company's Chimeric Antigen Receptor T-cell (CAR-T) pipeline for the treatment of cancer, as well as other types of therapeutic indications. It will be officially opened on 16 April.
Dr André Choulika, Founder, Chief Executive and Chairman of Cellectis, said New York City is one of the fastest-expanding biotech hubs in the world and the Alexandria Center for Life Science is surrounded by renowned academic and medical institutions, leading commercial companies in the life sciences industry as well as a robust financial market.
Cellectis uses gene editing to produce CAR-T cells with unique qualities and features, including allogeneic or 'off-the-shelf' versions, which can be produced more efficiently and shipped to patients worldwide.